SNOT-22 Calculator — Sino-Nasal Outcome Test
The SNOT-22 (Sino-Nasal Outcome Test-22) is a validated 22-item patient-reported outcome measure used to evaluate chronic rhinosinusitis (CRS) symptom severity and quality of life impact. It covers nasal, paranasal, sleep, and emotional domains.
About
The SNOT-22 questionnaire has been developed and validated over more than two decades of rhinology research, evolving from the original SNOT-16 (1999) and SNOT-20 (2004) versions. The current 22-item version was recommended by the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) as the standard patient-reported outcome measure for CRS clinical trials. Each item is rated on a 0-5 Likert scale (0 = no problem, 5 = problem as bad as it can be), yielding a total score from 0 to 110. Higher scores indicate greater symptom severity and quality of life impairment.
Formula
Total score = Sum of all 22 item scores (each 0-5). Range: 0-110.
The SNOT-22 covers five domains: nasal symptoms (need to blow nose, sneezing, runny nose, nasal obstruction, loss of smell/taste, thick nasal discharge), paranasal symptoms (cough, postnasal discharge, thick discharge from nose, ear fullness, dizziness, ear pain, facial pain/pressure), sleep dysfunction (difficulty falling asleep, waking up at night, lack of good night sleep, waking up tired, fatigue), emotional dysfunction (frustration/restlessness/irritability, sadness, feeling embarrassed), and productivity impact (reduced productivity, reduced concentration). Each item is scored from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of all 22 responses. A score of ≤10 suggests mild symptoms unlikely due to CRS. Scores 11-30 suggest mild-to-moderate impact. Scores 31-50 indicate moderate-to-severe impact. Scores 51-70 indicate severe impact. Scores >70 indicate very severe impact with major quality of life impairment.
Score Interpretation
The SNOT-22 is the most widely used patient-reported outcome measure in rhinology worldwide. Its psychometric properties have been extensively validated, demonstrating high test-retest reliability (ICC 0.94), excellent internal consistency (Cronbach's alpha 0.91), and strong construct validity against SF-36 and other quality of life measures. The minimal clinically important difference (MCID) for SNOT-22 is 8.9 points, meaning that a change of 9 or more points represents a meaningful clinical improvement. The SNOT-22 is the recommended outcome measure by EPOS (European Position Paper on Rhinosinusitis) and is used as the primary endpoint in most CRS clinical trials, including the landmark EMBRACE trial evaluating mepolizumab in nasal polyps, and multiple studies evaluating biologic therapies (dupilumab, omalizumab, benralizumab) for CRSwNP. The questionnaire's five domains allow clinicians to identify which symptom clusters are most problematic for individual patients (nasal, paranasal, sleep, emotional, productivity), enabling targeted therapy. A pre-treatment SNOT-22 score >30 is often used as a threshold for considering surgical intervention, and post-treatment improvement of >MCID (>9 points) indicates treatment success.
Mild — Symptoms unlikely due to CRS — 0–10
Occasional minor nasal symptoms with no significant impact on quality of life or sleep. CRS unlikely.
Management: Symptomatic management with saline nasal irrigation. Avoid triggers. Follow up if symptoms worsen.
Mild to Moderate — Possible CRS — 11–30
Symptoms noticeable but not severely impacting daily life. Possible mild CRS.
Management: Consider intranasal corticosteroids (mometasone or fluticasone). Saline irrigations. Allergy evaluation if atopic symptoms present.
Moderate — CRS Likely — 31–50
CRS significantly impacting quality of life. Medical therapy indicated.
Management: Initiate medical therapy: intranasal corticosteroids, saline irrigation. Consider CT sinus. ENT referral if no improvement in 4-6 weeks.
Severe — CRS Strongly Impacting Daily Life — 51–70
CRS severely affecting daily activities and sleep. Aggressive medical therapy indicated.
Management: Full medical therapy: intranasal corticosteroids, oral antibiotics if acute exacerbation, short oral corticosteroid course. CT sinus imaging. ENT referral.
Very Severe — CRS Causing Major Disability — 71–110
CRS causing major disability with severe impact on all aspects of life including sleep, work, and emotional well-being.
Management: Aggressive medical and possible surgical intervention. Urgent ENT specialist referral. CT sinus imaging. Functional endoscopic sinus surgery (FESS) may be indicated.
Reference Ranges
| Population | Normal Range | Notes |
|---|---|---|
| General reference for CRS severity | 0-110 | 0-10: Mild. 11-30: Mild-moderate. 31-50: Moderate. 51-70: Severe. 71-110: Very severe. |
Dr. Mahmoud El-Sayed
Dr. Mahmoud El-Sayed is a consultant otorhinolaryngologist with over 15 years of experience in clinical ENT practice.
View medical review board & editorial policy →Example Calculation
A 45-year-old male with chronic rhinosinusitis for 3 years completes the SNOT-22. His responses yield a total score of 64. Interpretation: Severe CRS strongly impacting daily life. Recommendation: Full medical therapy with intranasal corticosteroids, saline irrigations, and consideration of CT sinus imaging and ENT specialist referral.
Related Conditions
Related Medications
Common Mistakes
Using SNOT-22 as a diagnostic tool for CRS
SNOT-22 is a symptom severity and quality of life outcome measure, not a diagnostic tool. CRS diagnosis requires clinical criteria (symptoms ≥12 weeks, endoscopic/imaging findings) per EPOS or AAO-HNS guidelines. SNOT-22 should be used to assess symptom burden and treatment response, not to establish diagnosis.
Frequently Asked Questions
How is SNOT-22 different from SNOT-20?
What is the minimal clinically important difference (MCID) for SNOT-22?
References
- Hopkins C, Gillett S, Slack R, et al. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34(5):447-454. PubMed
- Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.